John A. Butera

1.3k citations

38 papers · 945 indexed · h-index 19

Organic Chemistry top 10%
- Chemical synthesis and alkaloids 5
- Synthesis and biological activity 3
Cellular and Molecular Neuroscience top 10%
- Neuroscience and Neuropharmacology Research 8
Urology top 10%
- Urinary Bladder and Prostate Research 5
Molecular Biology
- Chemical Synthesis and Analysis 5
- Connexins and lens biology 4
Biochemistry top 10%
Cardiology and Cardiovascular Medicine
- Cardiac electrophysiology and arrhythmias 9
Pathology and Forensic Medicine
- Cardiac Ischemia and Reperfusion 4

Co-authors: Thomas M. Argentieri N. Wesley Norton Jeffrey H. Sheldon Hassan Elokdah James K. Hennan Robert E. Swillo Schuyler Antane Bradford Hirth
Cited by: Organic Chemistry Cellular and Molecular Neuroscience Urology
Journals: Circulation (1 paper)Journal of Medicinal Chemistry (8 papers)Journal of Pharmacology and Experimental Therapeutics (3 papers)
Partner nations: United States Canada

In The Last Decade

John A. Butera

38 papers receiving 909 citations

Peers

Countries citing papers authored by John A. Butera

Since Specialization

Citations

This map shows the geographic impact of John A. Butera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Butera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Butera more than expected).

Fields of papers citing papers by John A. Butera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Butera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Butera. The network helps show where John A. Butera may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John A. Butera, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John A. Butera Line = papers co-authored together John A. Butera links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	De novo synthesis of teleocidin B analogs Tetrahedron ·Jun Pu,Kangwen Deng,John A. Butera,Michael Chlenov,A. Gilbert,Mike Kagan,James F. Mattes,Lynn Resnick	2010	5
2	Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors Bioorganic & Medicinal Chemistry Letters ·Andrew F. Donnell,Paul Dollings,John A. Butera,Arlene Dietrich,Kerri Lipinski,Afshin Ghavami,Warren D. Hirst	2010	36
3	The Gap Junction Modifier, GAP-134 [(2S,4R)-1-(2-Aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis Model Journal of Pharmacology and Experimental Therapeutics ·Eric I. Rossman,Kun Liu,Gwen A. Morgan,Robert E. Swillo,Julie A. Krueger,Stephen J. Gardell,John A. Butera,Matthew Gruver,Joel Kantrowitz,Hal S. Feldman,Jørgen S. Petersen,Ketil Haugan,James K. Hennan	2009	48
4	Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists European Journal of Pharmacology ·Julia Heinrich,John A. Butera,Tikva Carrick,Angela Krämer,Dianne Kowal,Tim Lock,Karen L. Marquis,Mark H. Pausch,Mike Popiolek,Shaiu-Ching Sun,Eugene Tseng,Albert J. Uveges,Scott C. Mayer	2009	83
5	Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents Bioorganic & Medicinal Chemistry Letters ·Eugene L. Piatnitski Chekler,John A. Butera,Li Di,Robert E. Swillo,Gwen A. Morgan,Eric I. Rossman,Christine Huselton,Bjarne Due Larsen,James K. Hennan	2009	8
6	Discovery of (2S,4R)-1-(2-Aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic Acid Hydrochloride (GAP-134)¹³, an Orally Active Small Molecule Gap-Junction Modifier for the Treatment of Atrial Fibrillation Journal of Medicinal Chemistry ·John A. Butera,Bjarne Due Larsen,James K. Hennan,Edward H. Kerns,Li Di,Asaf Alimardanov,Robert E. Swillo,Gwen A. Morgan,Kun Liu,Qiang Wang,Eric I. Rossman,Rayomand J. Unwalla,Leonard A. McDonald,Christine Huselton,Jørgen S. Petersen	2009	35
7	Prodrugs of Perzinfotel with Improved Oral Bioavailability Journal of Medicinal Chemistry ·Reinhardt B Baudy,John A. Butera,Magid Abou‐Gharbia,Hong Chen,Boyd L. Harrison,Uday Jain,Ronald L. Magolda,Jean Y. Sze,Michael R. Brandt,Terri Cummons,Diane Kowal,Menelas N. Pangalos,Bojana Zupan,Matthew Hoffmann,Michael J. May,Cheryl P. Mugford,Jeffrey D. Kennedy,Wayne E. Childers	2009	27
8	Novel progesterone receptor modulators with gene selective and context-dependent partial agonism Biochemical Pharmacology ·Thomas J. Berrodin,Scott A. Jelinsky,Nilsa Graciani,John A. Butera,Zhiming Zhang,Sunil Nagpal,Richard C. Winneker,Matthew R. Yudt	2008	18
9	Rotigaptide (ZP123) Prevents Spontaneous Ventricular Arrhythmias and Reduces Infarct Size During Myocardial Ischemia/Reperfusion Injury in Open-Chest Dogs Journal of Pharmacology and Experimental Therapeutics ·James K. Hennan,Robert E. Swillo,Gwen A. Morgan,James C. Keith,Robert G. Schaub,Robert P. Smith,Hal S. Feldman,Ketil Haugan,Joel Kantrowitz,Phil J. Wang,Aqel W. Abu‐Qare,John A. Butera,Bjarne Due Larsen,David L. Crandall	2006	71
10	Synthesis and bladder smooth muscle relaxing properties of substituted 3-amino-4-aryl-(and aralkyl-)cyclobut-3-ene-1,2-diones Bioorganic & Medicinal Chemistry Letters ·John A. Butera,Douglas J. Jenkins,Joseph R. Lennox,Jeffrey H. Sheldon,N. Wesley Norton,Dawn Warga,Thomas M. Argentieri	2005	13
11	Characterization of Novel Aryl-Ether, Biaryl, and Fluorene Aspartic Acid and Diaminopropionic Acid Analogs as Potent Inhibitors of the High-Affinity Glutamate Transporter EAAT2 Molecular Pharmacology ·John Dunlop,H. Beal McIlvain,Tikva Carrick,Brian Jow,Qiang Lü,Dianne Kowal,Steven Lin,Alexander Greenfield,Cristina Grosanu,Kristi Fan,Robert E. Petroski,John P. Williams,Alan C. Foster,John A. Butera	2005	45
12	ZP123 Prevents Spontaneous Ventricular Arrhythmias and Reduces Infarct Size During Myocardial Ischemia/Reperfusion Injury in Open-Chest Dogs James K. Hennan,Hal S. Feldman,Robert E. Swillo,Gwen A. Morgan,James C. Keith,Robert G. Schaub,Robert P. Smith,Ketil Haugan,Joel Kantrowitz,John A. Butera,David L. Crandall	2005	4
13	Synthesis and biological activities of aryl-ether-, biaryl-, and fluorene-aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT-2 Bioorganic & Medicinal Chemistry Letters ·Alexander Greenfield,Cristina Grosanu,John Dunlop,Beal McIlvain,Tikva Carrick,Brian Jow,Qiang Lu,Dianne Kowal,John P. Williams,John A. Butera	2005	28
14	Brain and plasma exposure profiling in early drug discovery using cassette administration and fast liquid chromatography-tandem mass spectrometry Journal of Pharmaceutical and Biomedical Analysis ·Meiyi Zhang,Edward H. Kerns,Oliver J. McConnell,June Sonnenberg‐Reines,Margaret M. Zaleska,J. Steven Jacobsen,John A. Butera,Anthony F. Kreft	2003	15
15	Convenient synthesis of functionalized terphenyls Tetrahedron Letters ·Alexander Greenfield,John A. Butera,Craig E. Caufield	2003	17
16	Design, Synthesis, and Biological Evaluation of Thio-Containing Compounds with Serum HDL-Cholesterol-Elevating Properties Journal of Medicinal Chemistry ·Hassan Elokdah,Theodore S. Sulkowski,Magid Abou‐Gharbia,John A. Butera,Sie‐Yearl Chai,Geraldine McFarlane,Mar‐Lee McKean,John Babiak,Steven J. Adelman,Elaine Quinet	2003	39
17	Synthesis and potassium channel opening activity of substituted 10H-Benzofuro[3,2-b]indole- and 5,10-Dihydro-indeno[1,2-b]indole-1-carboxylic acids Bioorganic & Medicinal Chemistry Letters ·John A. Butera,Schuyler Antane,Bradford Hirth,Joseph R. Lennox,Jeffrey H. Sheldon,N. Wesley Norton,Dawn Warga,Thomas M. Argentieri	2001	62
18	KCO-616 Drugs of the Future ·John A. Butera,Thomas M. Argentieri	2000	5
19	Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives Journal of Medicinal Chemistry ·John A. Butera,Walter Spinelli,Viji Anantharaman,Nicholas Marcopulos,Roderick W. Parsons,Issam F. Moubarak,Catherine Cullinan,Jehan F. Bagli	1991	24
20	Computer assisted design and synthesis of novel aldose reductase inhibitors Journal of Medicinal Chemistry ·John A. Butera,Jehan F. Bagli,Wendel W. Doubleday,Leslie G. Humber,Adi M. Treasurywala,Deborah A. Loughney,Kazimir Sestanj,Jane Millen,Janet Sredy	1989	11

About John A. Butera

John A. Butera is a scholar working on Urology, Cellular and Molecular Neuroscience and Biochemistry, having authored 38 papers that have together received 945 indexed citations. Recurring topics across this work include Cardiac electrophysiology and arrhythmias (9 papers), Neuroscience and Neuropharmacology Research (8 papers), Urinary Bladder and Prostate Research (5 papers), Chemical Synthesis and Analysis (5 papers), Chemical synthesis and alkaloids (5 papers), Connexins and lens biology (4 papers), Cardiac Ischemia and Reperfusion (4 papers) and Synthesis and biological activity (3 papers). The work is most often cited by research in Organic Chemistry (312 citations), Cellular and Molecular Neuroscience (175 citations) and Urology (55 citations). John A. Butera has collaborated with scholars based in United States and Canada. Frequent co-authors include Thomas M. Argentieri, N. Wesley Norton, Jeffrey H. Sheldon, Hassan Elokdah, James K. Hennan, Robert E. Swillo, Schuyler Antane, Bradford Hirth, John Dunlop and Eugene L. Piatnitski Chekler. Their work appears in journals such as Circulation, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact